What is the appropriate management approach for melasma in a 35-year-old non-pregnant female?

Management Approach for Melasma in a 35-Year-Old Female

Start with strict photoprotection and triple combination cream (hydroquinone 4%, tretinoin 0.05%, and corticosteroid) as first-line therapy, as this remains the most effective evidence-based treatment for melasma. 1, 2

Foundation: Photoprotection (Non-Negotiable)

Rigorous sun protection is mandatory and must be emphasized at every visit 1:

• Broad-spectrum SPF 50+ sunscreen applied every 2 hours during daylight
• Physical barriers (wide-brimmed hats, sun-protective clothing)
• Avoidance of peak UV hours (10 AM - 4 PM)
• This is not optional—melasma will recur without photoprotection regardless of treatment success

First-Line Treatment Algorithm

Initial 12-Week Trial

Triple combination cream (hydroquinone 4% + tretinoin 0.05% + fluocinolone acetonide 0.01%) applied once nightly 2:

• Most effective topical treatment with strongest evidence base
• If triple combination unavailable, use hydroquinone 4% monotherapy twice daily
• Alternative non-hydroquinone options: arbutin 1.5% + kojic acid 1% + azelaic acid 1.5% three times daily for week 1, twice daily for week 2, then once daily 3

Assess Response at 12 Weeks

Use Modified Melasma Area and Severity Index (mMASI) to quantify improvement 1:

• Good response (>50% improvement): Continue maintenance therapy with same regimen 2-3 times weekly
• Partial response (25-50%): Add adjunctive therapy (see below)
• Poor response (<25%): Consider refractory melasma approach

Second-Line: Adjunctive Therapies for Partial Responders

Platelet-Rich Plasma (PRP) Injections

Intradermal PRP shows superior efficacy compared to tranexamic acid injections 1:

• Protocol: Monthly intradermal microinjections 1 cm apart for 3-5 sessions
• Expect 53-54% reduction in mMASI score at 3 months post-treatment 1
• Can be used as monotherapy or combined with topical agents
• PRP + topical tranexamic acid cream yields better results than either alone 1

Oral Tranexamic Acid

For moderate-to-severe or recurrent melasma 2:

• Dosing: 250 mg twice daily for 3-6 months
• Promising systemic option but requires monitoring
• Contraindicated in thrombotic risk factors

Refractory Melasma (Failed First and Second-Line)

Combination Procedural Approach

Picosecond fractional laser + sodium hyaluronate microinjections 4:

• Three treatment sessions
• Demonstrated 55% reduction in MASI score (18.30 → 8.20) at 4 weeks
• 70% of patients show marked/moderate improvement
• Well-tolerated with only mild transient side effects

Alternative: Microneedling-Assisted Drug Delivery

Microneedling more effective than intradermal PRP injections alone for drug administration 1

Critical Management Principles

Melasma is a chronic relapsing condition requiring lifelong maintenance 1:

• Never discontinue photoprotection
• Maintenance therapy required even after clearance
• Regular follow-up every 3-6 months
• Recurrence is the rule, not the exception

Common Pitfalls to Avoid

1. Inadequate photoprotection counseling: Most treatment failures stem from poor sun protection compliance
2. Premature laser use: Chemical peels and laser therapies are equal or inferior to topicals with higher risk of post-inflammatory hyperpigmentation 2—reserve for refractory cases only
3. Insufficient treatment duration: Minimum 12 weeks needed to assess topical response
4. Stopping maintenance therapy: Leads to rapid recurrence
5. Ignoring skin type: Darker skin types (Fitzpatrick IV-VI) have higher PIH risk with aggressive procedures

Treatment Selection Based on Disease Severity

• Mild melasma: Topical triple combination or hydroquinone monotherapy + photoprotection
• Moderate melasma: Topicals + PRP injections (3-5 monthly sessions)
• Severe/refractory melasma: Topicals + PRP + consider picosecond laser with hyaluronate injections
• Recurrent melasma: Add oral tranexamic acid 250 mg twice daily

Monitoring and Follow-Up

• Baseline: Document with photography and mMASI score
• Week 4: Assess tolerance and adherence
• Week 12: Measure mMASI response, adjust therapy
• Maintenance phase: Every 3-6 months with continued photoprotection counseling

The evidence strongly supports starting conservatively with proven topical agents and strict photoprotection, escalating to PRP injections for inadequate responders, and reserving procedural interventions for truly refractory cases 1, 2.